撰文丨王聪 编辑丨王多鱼 排版丨水成文 慢性肾脏病 （ Chronic kidney disease， CKD） 是全球范围内最为严重且日益加剧的非传染性疾病之一，全球有 8%-14% 的成年人受其影响。慢性肾脏病 （CKD） 患者面临 终末期肾脏病 （ESKD） 的风险显著增加，同时发生重大心血管事件的易感性也更高。这些并发症的汇集导致了疾病各个阶段预后的严重恶 化，它每年导致约 260 万人死亡，其中 96 万人死于终末期肾脏病。 高尿酸血症 （ Hyperuricemia ） 以血清尿酸水平升高为特征，是慢性肾脏病 （CKD） 患者中常见且可改变的并发症。据调查，高尿酸血症在 CKD 患者中的患 病率是普通人群的 2 倍，此外，随着肾病分期的进展，高尿酸血症的患病率急剧上升。观察性数据还表明，高尿酸血症不仅与 CKD 的发生和加速进展有关，还 与该患者群体发生重大心血管事件和全因死亡率的风险增加有关。 然而，血清尿酸水平升高在肾脏功能恶化中的作用仍不清楚。因此， 降尿酸治疗 （ULT） 能否减缓合并高尿酸血症的 慢性肾脏病 （CKD） 患者的疾病进展， 仍有待验证。 2025 年 12 月 9 日，南方 ...

Core Viewpoint - The Hong Kong stock market for innovative drugs has seen a recent rebound, driven by positive developments from leading companies like BeiGene, 3SBio, and Innovent Biologics. Several innovative drug companies are seeking IPOs in Hong Kong, including Libang Pharmaceutical, which has recently submitted its listing application [1]. Group 1: Company Overview - Libang Pharmaceutical was founded in 2018 by Dr. Gavin Xia and Dr. Jin Tian, and it became a joint-stock company in October 2025, headquartered in Yangzhou, Jiangsu Province [3]. - The company has completed multiple financing rounds totaling approximately 2 billion RMB, with a post-money valuation of about 3.779 billion RMB as of October 2025 [4]. - Major investors include Tencent, Guojin Group, and several venture capital firms [4]. Group 2: Product Pipeline - Libang Pharmaceutical's product portfolio includes seven candidate products, three of which are in clinical stages, and one commercialized product [8]. - The core product, AP301, is a phosphate binder for treating hyperphosphatemia, with significant unmet medical needs in chronic kidney disease (CKD) [11]. - AP301 has completed Phase III clinical trials in China and is expected to submit a New Drug Application (NDA) to the National Medical Products Administration in the first half of 2026 [11]. Group 3: Financial Performance - The company reported revenues of 0, 6.5 million, and 12.11 million RMB for the years 2023, 2024, and the first half of 2025, respectively, all derived from AP601 sales [22]. - Cumulative losses over two and a half years amount to 910 million RMB, primarily due to R&D expenditures [23]. - As of June 30, 2025, the company had cash and cash equivalents of 171 million RMB, sufficient to cover at least 125% of its costs for the next 12 months [25]. Group 4: Market Potential and Risks - The global market for hyperphosphatemia drugs is projected to reach 1.5 billion USD by 2024, with the Chinese market expected to reach 2.4 billion RMB [17]. - There is a significant overlap in the target markets for AP301 and AP306, which may lead to potential market cannibalization risks [18]. - The chronic kidney disease sector has unmet clinical needs, but compared to oncology and autoimmune diseases, the market space is relatively smaller [27].

Core Viewpoint - Renal anemia is a common complication in chronic kidney disease (CKD) patients, and understanding its mechanisms, diagnosis, treatment, and management is crucial for improving patient outcomes [2][3][4][5][6] Group 1: Mechanism and Impact of Renal Anemia - Renal anemia is primarily linked to impaired kidney function, leading to reduced erythropoietin (EPO) production, which in turn suppresses bone marrow activity and decreases red blood cell production [2] - Accumulation of uremic toxins further destabilizes red blood cell membranes, shortening their lifespan and exacerbating anemia [2] - If not addressed, chronic anemia can result in tissue hypoxia, accelerating kidney function decline and increasing cardiovascular risks, including left ventricular hypertrophy and heart failure [2] Group 2: Diagnosis and Treatment Principles - Diagnosis of renal anemia involves assessing hemoglobin levels, with thresholds set at <130 g/L for men and <120 g/L for non-pregnant women [3] - Treatment goals aim to maintain hemoglobin levels between 110-130 g/L, correcting reversible factors like iron deficiency and infections [3] - Early diagnosis and treatment are emphasized to improve quality of life and reduce hospitalization and dialysis needs [3] Group 3: Advances in HIF-PHI Drug Therapy - Traditional treatments for renal anemia rely on injected EPO and iron supplements, which may lead to reduced efficacy over time due to antibody formation [4] - HIF-PHI drugs represent a significant advancement, offering oral administration that enhances patient compliance and reduces treatment burden [4] - These drugs not only stimulate endogenous EPO production but also improve iron absorption and counteract chronic inflammation's negative effects on hematopoiesis [4] Group 4: Daily Management and Self-Monitoring - Effective long-term management of renal anemia requires lifestyle adjustments, including a diet rich in iron and vitamin C, moderate exercise, and regular monitoring of hemoglobin and iron levels [5] - Patients are advised to consume iron-rich foods while avoiding substances like tea and coffee that can inhibit iron absorption [5] - Regular check-ups are recommended, with intervals adjusted based on treatment status to ensure timely modifications to therapy [5] Group 5: Future Directions and Public Awareness - Despite advancements in treatment, there remains room for improvement in achieving target hemoglobin levels among patients in China [6] - Increased public education and standardized treatment protocols are essential for enhancing patient quality of life and reducing complications [6] - Regular screening for anemia in CKD patients is crucial for early detection and management [6]

Core Viewpoint - Renal anemia is a common complication in chronic kidney disease (CKD) patients, significantly affecting their quality of life and increasing the risk of cardiovascular events and mortality [1] Group 1: Disease Overview - Approximately 50% of CKD patients in China experience anemia, with incidence rates rising as kidney function deteriorates [1] - The underlying causes of renal anemia include insufficient erythropoietin (EPO) production, iron metabolism disorders, and inflammation [1] - Symptoms of renal anemia include fatigue, palpitations, and reduced exercise tolerance [1] Group 2: Treatment Challenges - Current treatment options include iron supplementation, erythropoiesis-stimulating agents (ESA), and oral HIF-PHI drugs [1] - Patients face challenges such as iron deficiency, ESA resistance, and poor treatment adherence [1] - Some patients delay diagnosis and treatment due to a lack of awareness or reliance on blood transfusions [1] Group 3: Expert Insights - A live session featuring experts in nephrology will be held to discuss the standardized diagnosis and treatment of renal anemia, aiming to help patients and families respond scientifically and improve quality of life [1][2]